Status:
RECRUITING
East Asian Breast Cancer Genome Atlas and Recurrence Risk Prediction
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Breast Cancer
Eligibility:
All Genders
20+ years
Brief Summary
This project aims to establish the cancer genome atlas and the platform of recurrence risk prediction specific for East Asian breast cancer patients. The study was planned to collect blood sample, fre...
Eligibility Criteria
Inclusion
- 1\. Aged more than 20-year-old at the time of informed consent.
- 2\. An unconfirmed breast tumor, or have histologically confirmed invasive breast cancer.
- 3\. Have radiological or objective evidence of breast tumor size ≥1 cm.
- 4\. Be able to comply with study procedures to collect the clinical medical information, blood sample, fresh tumor tissue, and 12 sections of paraffin embedded tumor tissue.
- 5\. Be able to sign an informed consent.
Exclusion
- 1\. Have histologically confirmed ductal carcinoma in situ (DCIS).
- 2\. Stage I, II or III breast cancer patients who have received neoadjuvant treatments, including chemotherapy, hormonal therapy, or targeted therapy.
- 3\. Stage IV or metastatic breast cancer patients who have received chemotherapy.
Key Trial Info
Start Date :
October 18 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2028
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT04344496
Start Date
October 18 2018
End Date
July 1 2028
Last Update
September 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100